Source comparison
TB-500 Dosage Fibrosis Reduction: Protocol Comparison
Cardiac fibrosis (murine, post-MI) 6mg/kg twice weekly Subcutaneous, every 3–4 days 8 weeks 34% reduction in collagen deposition (histology) Effective for acute cardiac remodeling; requires consistent twice-weekly dosing to maintain plasma levels Hepatic fibro
This comparison does not assign a generated winner or score.
- Cardiac fibrosis (murine, post-MI)
- 6mg/kg twice weekly
- Subcutaneous, every 3–4 days
- 8 weeks
- 34% reduction in collagen deposition (histology)
- Effective for acute cardiac remodeling; requires consistent twice-weekly dosing to maintain plasma levels
- Hepatic fibrosis (CCl4-induced)
- 30mg/kg cumulative (split doses)
- Subcutaneous, twice weekly
- 4 weeks
- 41% reduction in fibrosis scoring
- Higher cumulative dose reflects hepatic ECM density; slower tissue turnover requires longer protocols
- Pulmonary fibrosis (bleomycin model)
- 4mg twice weekly
- 29% reduction in Ashcroft score
- Pulmonary tissue shows slower remodeling than cardiac; results appear week 3+
- Dermal fibrosis (scleroderma model)
- 2mg three times weekly
- Subcutaneous, local injection
- 6 weeks
- 22% reduction in dermal thickness
- Local administration concentrates peptide at fibrotic site; systemic dosing less effective for localized fibrosis